Biological therapies of systemic lupus erythematosus;Biologiczne terapie tocznia rumieniowatego układowego

Polski Merkuriusz Lekarski

Volumn 20, Issue 117, 2006, Pages 371-373

  Olesińska, Marzena ^a   Chwalińska Sadowska, Hanna ^a   Mielnik, Paweł ^a   Wiȩsik Szewczyk, Ewa ^a  

^a INSTITUTE OF RHEUMATOLOGY   (Poland)

Author keywords

Biological therapies; Systemic lupus erythematosus

Indexed keywords

ABATACEPT; ABETIMUS; ANTIBODY; B7 ANTIGEN; BELIMUMAB; BG 9588; CD28 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; CD86 ANTIGEN; COMPLEMENT; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C9; COMPLEMENT MEMBRANE ATTACK COMPLEX; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; DNA ANTIBODY; GLUCOCORTICOID; IDEC 131; IMMUNOGLOBULIN; INTERLEUKIN 10; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PLACEBO; PREDNISOLONE; RITUXIMAB; T LYMPHOCYTE RECEPTOR;

ANTIBODY PRODUCTION; B LYMPHOCYTE ACTIVATION; BIOLOGICAL THERAPY; COMPLEMENT ACTIVATION; CYTOKINE PRODUCTION; DRUG MECHANISM; IMMUNITY; PATHOGENESIS; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

ANTIGEN-ANTIBODY COMPLEX; BIOLOGICAL PRODUCTS; COMPLEMENT ACTIVATION; CYTOKINES; HUMANS; IMMUNOTHERAPY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 33645697428     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Alarçon-Segovia D., Tumlin J.A., Furie R.A. i wsp.: LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus. Arthritis Rheum., 2003, 48, 442-454.
2. Anolik J.H., Campbell D., Felgar R. i wsp.: B lymphocyte depletion in the treatment of systemic lupus (SLE), phase I/II trial of Rituximab (Rituxan in SLE). Arthritis Rheum., 2002, 46, 717.
3. Boumpas D.T., Furie R., Manzi S. i wsp.: A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum., 2003, 48, 719-727.
4. Cheema G.S., Roschke V., Hilbert D.M. i wsp.: Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum., 2001, 44, 1313-1319.
5. Davis J.C., Totoritis M.C., Rosenberg J. i wsp.: Phase I clinical trial of monoclonal antibody against CD40L (IDEC-131) in patients with systemic lupus erythematosus. J. Rheumatol., 2001, 28, 95-101.
6. Do R.K., Hatada E., Lee H. i wsp.: Attenuation of underlies B lymphocyte stimulator enhancement of humoral immune response. J. Exp. Med., 2000, 192, 953-964.
7. Furie R.A., Cash J.M., Cronin M.E. i wsp.: Treatment of systemic lupus erythematosus with LJP 394. J. Rheumatol., 2001, 28, 257-265.
8. Furie R., Matis L., Rollins S. i wsp.: A single dose, placebo-controlled, double blind, phase I study of the humanized anti-C5 antibody hbG1.1 in patient with systemic lupus erythematosus. Abstract presented at The 64th Annual Scientific Meeting of the American College of Rheumatology. Philadelphia. PA.
9. Furie R.A., Stohl W., Ginzler E. i wsp.: Safety, pharmacokinetic and pharmacodynamic results of a phase I single and double dose - escalation study of LymphoStat-B (human monoclonal antibody to BLyS) in SLE patients. Arthritis Rheum., 2003, 48, 377.
10. Gesuck B.D., Davis J.C.: Novel therapeutic agents for systemic lupus erythematosus. Curr. Opin. Rheumatol., 2002, 14, 5, 515-521.
11. Helm K.F., Peters M.S.: Deposition of membrane attack complex in cutaneous lesions of lupus erythematosus. J. Am. Acad. Dermatol., 1993, 28, 687-691.
12. Hirashima M., Fazukawa T., Abe K. i wsp.: Expression and activity analyses of CTLA4 in peripheral blood lymphocytes in systemic lupus erythematosus patients. Lupus, 2004, 13, 24-31.
13. Kalunian K.C., Davis J.C., Marril J.T. i wsp.: IDEC-131 Lupus Study Group. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomised, double-blind, placebo-controlled trial. Arthritis Rheum., 2002, 46, 3251-3258.
14. Kawai T., Andrews D., Colvin R.B. i wsp.: Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat. Med., 2000, 6, 114.
15. Leandro M.J., Edwards J.C., Cambridge G. i wsp.: An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum., 2002, 46, 2673-2677.
16. Leandro M.J., Ehrenstein M.R., Edwards M.R. i wsp.: Treatment of refractory lupus nephritis with B lymphocyte depletion. Arthritis Rheum., 2003, 48, 378.
17. Linker-Israeli M., Deans D.J., Wallace D.J. i wsp.: Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J. Immunol., 1991, 147, 117-123.
18. Llorente L., Richaud-Patin Y., Garcia-Padilla C. i wsp.: Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum., 2000, 43, 1790-1800.
19. Moore P.A., Belvedere O., Orr A. i wsp.: BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science, 1999, 285, 260-263.
20. Perrotta S., Locatelli F., La Manna A. i wsp.: Anti-CD20 monoclonal antibody (rituximab) for life threatening autoimmune hemolytic anemia in a patient with systemic lupus erythematosus. Br. J. Haematol., 2002, 116, 465-467.
21. Quigg R.J.: Complement and the kidney. J. Immunol., 2003, 171, 3319-3324.
22. Rother R.P., Mojcik C.F., McCroskery E.W.: Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosus. Lupus, 2004, 13, 328-334.
23. Saito K., Nawata M., Nakayamada S. i wsp.: Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life threatening refractory systemic lupus erythematosus with renal and central nervous system involvement. Lupus, 2003, 12, 798-800.
24. Stohl W.: Systemic lupus erythematosus: a blissless disease of too much BLyS (B lymphocyte stimulator) protein. Curr. Opin. Rheumatol., 2002, 14, 522-528.
25. Thompson J.S., Schneider P., Kalled S.L. i wsp.: BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population. J. Exp. Med., 2000, 192, 129-135.
26. Tsai C.Y., Wu T.H., Yu C.L. i wsp.: Increased excretions of beta2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis. Nephron, 2000, 85, 207-214.
27. Weide R., Heymanns J., Pandorf A. i wsp.: Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy. Lupus, 2003, 12, 779-782.
28. Yazdany J., Davis J.: The role of CD40 ligand in systemic lupus erythematosus. Lupus, 2004, 13, 377-380.
29. Yellin M.J., D'Agati V., Parkinson G. i wsp.: Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritides. Arthritis Rheum., 1997, 40, 124-134.
30. Zhang J., Roschke V., Baker K. i wsp.: Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J. Immunol., 2001, 166, 6-10.